Novo Nordisk stock tests $49.13 support amid US FDA compounding restrictions

Traders Union
All News
Financial News
Novo Nordisk slips 0.38% to $49.28

Highlights

Novo Nordisk has repurchased nearly 24 million B shares since February 2026, reducing float and supporting per-share value growth.
FDA actions and legal steps against telehealth compounders aim to protect semaglutide and liraglutide branded revenues amid ongoing IP defense.
Price is expected to trade between $48.41 and $50.15 with technical signals showing bullish momentum and strong support limiting downside risk.

Buybacks and regulatory actions drive per-share value and IP defense

Novo Nordisk A/S has executed significant buybacks, repurchasing 23,984,179 B shares since February 2026 and holding a total of 41,169,480 B shares as treasury as of July 10, 2026, according to Tipranks. This ongoing reduction in floating shares can enhance per-share metrics and reflects management’s use of capital to return value to shareholders. Separately, the U.S. FDA’s proposal to formally exclude semaglutide and liraglutide products from the 503B bulks list, as reported by Pharmacytimes, limits large-scale compounding by third parties, potentially protecting branded revenues. Novo Nordisk has also filed a lawsuit against Hims & Hers, pursuing legal action over alleged telehealth-driven compounding of GLP-1 drugs and patent infringement, as stated by Medicaleconomics, underscoring continued efforts to defend its intellectual property.

Mixed technical momentum as short-term averages, signals diverge

On the hourly chart, NVO is positioned above the 20-period moving average but remains below the 50-period level, while maintaining a stance above the 200-period moving average on the daily timeframe. Immediate support is offered by the Ichimoku Kijun at $49.13. Momentum studies reveal strong bullish signals from the Moving Average Convergence Divergence (MACD), with the Average Directional Index (ADX) showing no clear trend strength. The Relative Strength Index (RSI) is at 50.48 with a buy indication, whereas both the Stochastic RSI and Commodity Channel Index (CCI) are neutral, suggesting an absence of pronounced overbought or oversold signals. Bull/Bear Power is positive, indicating slight buyer dominance in intraday trade, while the Awesome Oscillator is neutral and does not confirm any decisive bias.

Higher upside probability as volatility narrows near support

Looking ahead, NVO is likely to remain in a sideways corridor with moderate volatility, with a typical volatility band expected between $48.41 and $50.15 for the coming several days. The probability of an upward move is considerably higher than a bearish reversal, while the downside risk appears low unless price breaks decisively below immediate support at $49.13. Sustained bullish momentum would require a move above resistance, while a break below support may signal the start of a new downward scenario.

Viktoras Karapetjanc, expert at Traders Union, sees Novo Nordisk’s buyback program and U.S. regulatory tailwinds as positive for long-term shareholder value. He believes the company’s aggressive approach to defending its intellectual property and maintaining branded exclusivity supports a constructive outlook. Technically, near-term movement is likely to stay in a tight range above $49.13, unless a clear break occurs. Upside potential stands out while downside risks seem contained for now. "With fundamentals strong and regulatory winds at Novo Nordisk’s back, I remain optimistic about sustained value growth for NVO."

Earlier, analysts noted that Novo Nordisk shares were exhibiting sustained upward momentum, though short-term exhaustion remained a risk if resistance was not decisively cleared. The current analysis strengthens this outlook by highlighting continued buyer dominance and neutral momentum signals, with immediate attention warranted toward the $49.13 support as a potential inflection point for future price action.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.